MYND Life Sciences Inc. Has Management CTO Revoked

Rhea-AI Summary

MYND Life Sciences announces the revocation of its Management Cease Trade Order after filing necessary financial statements.

Positive

• Revocation of the Management Cease Trade Order will allow trading in MYND securities to resume.

Negative

• None.

Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order.

In accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") MYND is giving the following update:
On March 1, 2023, the Company announced that it applied for a management cease trade order ("MCTO") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Annual Audited Financial Statement, the Required Filing, for the year ended October 31, 2022 by the applicable filing deadlines. The MCTO was issued on March 1, 2023 and restricted all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company.

Mynd is pleased to announce that under section 164 of the Securities Act the MCTO has been revoked upon the filing of all necessary documentation including the Annual Audited Financial Statements and Q1 Financial Statements. Mynd is now up to date on all filings.

The Company would like to thank all management for their diligence in achieving this timeline.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.

For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact-us.

CONTACT INFORMATION

Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/165412

FAQ

What is the Management Cease Trade Order?

The Management Cease Trade Order is a restriction on trading in securities of a company by its Chief Executive Officer and Chief Financial Officer.

Why was the MCTO issued for MYND Life Sciences?

MYND Life Sciences applied for the MCTO because it was unable to file its Annual Audited Financial Statement by the filing deadlines.

What is the significance of revoking the MCTO?

Revoking the MCTO allows trading in MYND securities to resume, indicating that the company is now up to date on its financial filings.